NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM

• NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed/refractory multiple myeloma

Biological:

PHE885

Sponsor:

Novartis Pharmaceuticals

---

ClinicalTrials.gov Identifier: NCT04318327

Official Title: Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

First Posted : March 23, 2020

Click here for details on ClinicalTrials.gov

---

BCMA-directed Autologous CAR-T Cells PHE885

Autologous Anti-BCMA CAR T-cells PHE885 (Code C174124)

Autologous Anti-BCMA CAR T-cells PHE885

Autologous BCMA-specific CAR T-cells PHE885

BCMA-directed Autologous CAR-T Cells PHE885

PHE 885

PHE-885

PHE885

---

Autologous Anti-BCMA CAR T-cells PHE885

- Illinois: University of Chicago

- Massachusetts: Massachusetts General Hospital Boston

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

---

3864 Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-ChargeTM Platform

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster III

Hematology Disease Topics & Pathways:

Biological, Adults, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Myeloid Malignancies, Study Population

Monday, December 13, 2021, 6:00 PM-8:00 PM

Click here for details

---

Locations

United States, Illinois

United States, Massachusetts

United States, Wisconsin